{"id":"W4320486696","doi":"10.1158/1535-7163.mct-22-0583","title":"A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Cancer Institute, University of Pittsburgh; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; University of Texas MD Anderson Cancer Center; Pfizer; Yale Cancer Center; Merck KGaA; Princess Margaret Cancer Foundation; Johns Hopkins University; Dana-Farber/Harvard Cancer Center; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Regeneron Pharmaceuticals; California Space Grant Consortium","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Radium-223; Cancer; Adverse effect; Urology; Bone metastasis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003100543,0.0003143499,0.0006121214,0.0003533236,0.00008014023,0.00003676257,0.00008225703,0.00004490881,0.00003610399],"category_scores_gemma":[0.000004574245,0.000244709,0.00004162438,0.001220835,0.0001805748,0.0001269743,0.00002124701,0.0002203427,0.000001075799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002341144,"about_ca_system_score_gemma":0.000395094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001318282,"about_ca_topic_score_gemma":0.001476148,"domain_scores_codex":[0.997835,0.0001925494,0.0004922824,0.0004492798,0.0006759643,0.0003549166],"domain_scores_gemma":[0.9989492,0.00006250216,0.0002844494,0.0003576556,0.0002348152,0.0001113532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02752337,0.01346267,0.03768295,0.001256535,0.006427654,0.002482248,0.02933307,0.005162602,0.8345515,0.0006744548,0.0002311846,0.04121173],"study_design_scores_gemma":[0.3490885,0.03857708,0.05855471,0.002774436,0.006944751,0.0002456414,0.02443742,0.01621565,0.4955504,0.0009463612,0.004424769,0.002240392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919931,0.003699874,0.0003027087,0.001429578,0.00003816186,0.002229365,0.000153305,0.00007125553,0.00008265637],"genre_scores_gemma":[0.9969482,0.00100037,0.0003400525,0.0004165116,0.00001654886,0.001009559,0.00006582576,0.00007689388,0.0001260837],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3390012,"threshold_uncertainty_score":0.9978945,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04713190019167467,"score_gpt":0.3570710466000965,"score_spread":0.3099391464084219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}